KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Health-related quality of life and performance status with NALIRIFOX versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma: results from the NAPOLI 3 trial.

D Melisi, T Macarulla, C De La Fouchardière, R A Pazo Cid, S R Chandana, I Kiss, W J Lee, T O Goetze, E Van Cutsem, A S Paulson, T Bekaii-Saab, S Pant, R A Hubner, F Maxwell, L Zhang, F Benzaghou, E M O'Reilly, Z A Wainberg

ESMO Open 10(8) 105534

PMID40763412
PMCIDPMC12345255
DOI10.1016/j.esmoop.2025.105534
发表日期2025-08-05
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

BACKGROUND: In NAPOLI 3 (NCT04083235), first-line (1L) liposomal irinotecan plus 5-fluorouracil/leucovorin plus oxaliplatin (NALIRIFOX) demonstrated statistically significant improvements in overall survival and progression-free survival compared with gemcitabine plus nab-paclitaxel (Gem + NabP) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). In this exploratory analysis, health-related quality of life (HRQoL) and performance status (PS) outcomes from NAPOLI 3 were evaluated. MATERIALS AND METHODS: HRQoL was assessed at baseline, day 1 of each treatment cycle, and at end of treatment (EoT) using the European Organisation for Research and Treatment of Cancer Quality of Life core questionnaire (EORTC QLQ-C30). Analyses included patients who provided baseline and at least one subsequent assessment. A mixed model for repeated measures was used to describe score evolution over time between treatment arms. Eastern Cooperative Oncology Group (ECOG) PS was recorded in the intention-to-treat (ITT) population at baseline, days 1, 8, and 15 of each treatment cycle, and EoT. Time to deterioration (TTD) in EORTC QLQ-C30 and ECOG PS scores was estimated using the Kaplan-Meier methodology. RESULTS: Overall, 245 patients in the NALIRIFOX arm (ITT population, n = 383) and 232 patients in the Gem + NabP arm (n = 387) provided baseline and at least one subsequent EORTC QLQ-C30 assessment. There was an initial decline in global health status (GHS) from baseline to week 12 across both treatment arms [least-squares mean -2.4, 95% confidence interval (CI) -5.9 to 1.1; Gem + NabP: -0.7 (-4.2 to 2.9)], with no further deterioration from week 16 onwards. TTD in GHS (hazard ratio 0.74, 95% CI 0.53-1.04, nominal P = 0.08) and ECOG PS score (hazard ratio 0.72, 95% CI 0.55-0.92, nominal P = 0.009) was longer with NALIRIFOX than with Gem + NabP. CONCLUSIONS: These data suggest that 1L NALIRIFOX provides efficacy benefits for patients with mPDAC without compromising HRQoL or PS compared with Gem + NabP.

KM 提取结果

2 个 Figure · 2 个 KM 面板

进入结果中心
KM Figure1 个面板

Figure 2

Figure 2 Kaplan–Meier estimate of TUDD in EORTC QLQ-C30 global health status score (EORTC QLQ-C30 population). CI, confidence interval; EORTC QLQ-C30, European Organisation for Research and Treatment of Cancer Quality of Life core questionnaire; Gem, gemcitabine; HR, hazard ratio; NA, not available; NabP, nab-paclitaxel; NALIRIFOX, liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin; QoL, quality of life; TUDD, time until definitive deterioration.

Figure_2_Kaplan_Meier_estimate_of_TUDD_in_EORTC_QLQ-C30_global_health_status_score

time until definitive deterioration in global health status QoL

Figure 2 · Panel Figure_2_Kaplan_Meier_estimate_of_TUDD_in_EORTC_QLQ-C30_global_health_status_score

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel Figure_2_Kaplan_Meier_estimate_of_TUDD_in_EORTC_QLQ-C30_global_health_status_score 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
KM Figure1 个面板

Figure 4

Figure 4 Kaplan–Meier estimate of TTD in ECOG PS score. CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; Gem, gemcitabine; HR, hazard ratio; NabP, nab-paclitaxel; NALIRIFOX, liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin; NE, not evaluable; NR, not reached; TTD, time to deterioration.

TTD_in_ECOG_PS

time to deterioration in ECOG PS

Figure 4 · Panel TTD_in_ECOG_PS

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel TTD_in_ECOG_PS 是同一 Figure 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1 Least-squares mean change from baseline in EORTC QLQ-C30 global health status and functional scale scores a over time (left) and symptom scale scores b (right) over time (EORTC QLQ-C30 population) . EORTC QLQ-C30, European Organisation for Research and Treatment of Cancer Quality of Life core questionnaire; Gem, gemcitabine; GHS, global health status; NabP, nab-paclitaxel; NALIRIFOX, liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin. a Higher scores indicate improvement. b Lower scores indicate improvement. c Values obtained every 4 weeks.
非 KM Figure
Figure 3Figure 3 TUDD in selected EORTC QLQ-C30 scale scores (EORTC QLQ-C30 population). CI, confidence interval; EORTC QLQ-C30, European Organisation for Research and Treatment of Cancer Quality of Life core questionnaire; Gem, gemcitabine; HR, hazard ratio; NA, not available; NabP, nab-paclitaxel; NALIRIFOX, liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin; TUDD, time until definitive deterioration.
非 KM Figure